Wilex’s Heidelberg Pharma in First ADC Deal with Roche
By Cormac Sheridan
Tuesday, September 3, 2013
MUNICH, Germany – Shares in Wilex AG gained as much as 12 percent Monday on news that its subsidiary, Heidelberg Pharma GmbH, entered a research collaboration and option agreement with Roche Holding AG, based on its preclinical antibody-drug conjugate (ADC) technology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.